Publicaciones (224) Publicaciones de José Ramón Azanza Perea

2024

  1. Fármacos antifúngicos

    Castells Hernández farmacología en enfermería (Elsevier), pp. 592-604

  2. Fármacos antivirales

    Castells Hernández farmacología en enfermería (Elsevier), pp. 605-620

2021

  1. Liposomal amphotericin B: Clinical pharmacology, pharmacokinetics and pharmacodynamics

    Revista Iberoamericana de Micologia

  2. Recommendations for antibiotic selection for severe nosocomial infections

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 34, Núm. 5, pp. 511-524

  3. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

    Mycoses, Vol. 64, Núm. 1, pp. 66-77

2020

  1. Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 45, Núm. 2, pp. 265-272

  2. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 174-181

  3. Single-Institution Experience in Clinical Trials during the COVID-19 Pandemic in Spain: Not So Bad after All?

    JCO Global Oncology

  4. The sars-cov-2 ivermectin navarra-isglobal trial (saint) to evaluate the potential of ivermectin to reduce covid-19 transmission in low risk, non-severe covid-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

    Trials, Vol. 21, Núm. 1

2019

  1. Ceftobiprole: pharmacokinetics and PK/PD profile

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 32, pp. 11-16

  2. La «siemprefiesta»

    Et nunc et semper festa (EUNSA. Ediciones Universidad de Navarra, S.A.), pp. 9-12

  3. The pharmacodynamic bases of the prescription of antimicrobials

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 32, pp. 35-37

2018

  1. Antibiotic selection in the treatment of acute invasive infections by pseudomonas aeruginosa: Guidelines by the Spanish society of chemotherapy

    Revista Espanola de Quimioterapia, Vol. 31, Núm. 1, pp. 78-100

  2. Antibióticos B-lactámicos

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 729-750

  3. Antibióticos aminoglucósidos, tetraciclinas, rigeciclina y cloranfenicol

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 751-770

  4. Antibióticos macrólidos y otros antibióticos

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 771-788

  5. Antibióticos. Generalidades

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 715-728

  6. Pharmacological profile of isavuconazole

    Revista Iberoamericana de Micologia

2017

  1. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in spain

    ClinicoEconomics and Outcomes Research, Vol. 9, pp. 39-47

  2. Dalbavancina: parámetros farmacocinéticos y farmacodinámicos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, pp. 22-27